Clinical Research Directory

Inclusion Criteria: * Diagnosed with type 1 diabetes or with type 2 diabetes and using insulin for at least 90 days at the time of enrollment * Stable insulin regimen type in the last 90 days prior to enrollment * Stable insulin doses for the last 30 days prior to enrollment * Willing to use only compatible rapid-acting or ultra rapid-acting insulin in the iLet for the duration of the study * Stable regimen of non-insulin glucose lowering medications over the preceding 90 days prior to enrollment * Stable doses of non-insulin glucose lowering medications over the last 30 days prior to enrollment * Willing to not change doses from baseline non-insulin glucose lowering medications during the trial unless required for safety or tolerability purposes * Willing to not initiate use of any new non-insulin glucose-lowering during the trial * Able to read and understand English Exclusion Criteria: * Unable to provide informed consent * Unable to safely comply with study procedures and reporting requirements * For people with type 1 diabetes: Current use of any non insulin glucose lowering medications other than metformin or GLP-1 receptor agonists * For people with type 2 diabetes: Current use of sulfonylurea or meglitinide medications * Use of medication or supplements that are known to interfere with CGM sensor accuracy and, in the opinion of the treating physician, cannot be discontinued during the study period * Known hemoglobinopathy or condition/medication use that would interfere with accurate determination of HbA1c, in the investigator's opinion * History of cystic fibrosis, diabetes secondary to pancreatitis, or other pancreatic diseases, including pancreatic tumor or insulinoma, or history of complete pancreatectomy * Tape allergy or skin condition that will preclude use of the study pump or CGM * Pregnant or lactating, planning to become pregnant during the study, or sexually active without the use of appropriate contraception * Most recent (within the last 2 years) estimated glomerular filtration rate (eGFR) \< 30 ml/min OR currently in renal failure on dialysis * Current participation in another diabetes-related interventional clinical trial * Presence of a medical condition or use of a medication that, in the judgment of the site investigator, principal investigator (PI), or medical monitor, could compromise the results of the study or the safety of the participant. * Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment. * .Participant is an employee of Beta Bionics, an Investigator or Investigator's study team, or immediate family member